Middle East Undiscovered Gems And 2 Other Promising Stocks With Strong Potential

Simply Wall St · 1d ago

As most Gulf markets have recently ended higher, buoyed by potential U.S. tariff exemptions, investors are closely watching the Middle East for emerging opportunities amid ongoing trade tensions and fluctuating oil prices. In this dynamic environment, identifying promising stocks involves looking at companies with robust fundamentals that can thrive despite external economic pressures and capitalize on regional growth prospects.

Top 10 Undiscovered Gems With Strong Fundamentals In The Middle East

Name Debt To Equity Revenue Growth Earnings Growth Health Rating
Amir Marketing and Investments in Agriculture 13.05% 5.82% 3.78% ★★★★★★
Payton Industries NA 8.38% 15.66% ★★★★★★
Formula Systems (1985) 34.50% 9.19% 12.63% ★★★★★★
Terminal X Online 18.34% 17.80% 32.47% ★★★★★★
Analyst I.M.S. Investment Management Services NA 23.69% 28.47% ★★★★★★
Saudi Azm for Communication and Information Technology 2.07% 16.18% 21.11% ★★★★★★
National General Insurance (P.J.S.C.) NA 13.40% 30.21% ★★★★★☆
Malam - Team 91.23% 12.11% -6.38% ★★★★★☆
C. Mer Industries 114.92% 13.32% 73.44% ★★★★☆☆
Aura Investments 180.44% 9.48% 43.42% ★★★★☆☆

Click here to see the full list of 244 stocks from our Middle Eastern Undiscovered Gems With Strong Fundamentals screener.

Let's review some notable picks from our screened stocks.

Middle East Pharmaceutical Industries (SASE:4016)

Simply Wall St Value Rating: ★★★★★☆

Overview: Middle East Pharmaceutical Industries Company focuses on the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations both within Saudi Arabia and internationally, with a market cap of SAR2.59 billion.

Operations: Middle East Pharmaceutical Industries generates revenue primarily from the sale of generic medicines and pharmaceutical preparations. The company's cost structure includes expenses related to research, development, and manufacturing processes. Its net profit margin has shown variability over recent periods, reflecting changes in operational efficiency and market conditions.

Middle East Pharmaceutical Industries, a smaller player in the sector, has shown notable performance with earnings growth of 21% over the past year, outpacing the broader industry's 4.6%. Its net debt to equity ratio stands at a satisfactory 11.6%, indicating prudent financial management. The company's EBIT covers interest payments 24 times over, reflecting strong operational efficiency. Recent earnings announcements revealed sales of SAR 394 million and net income of SAR 79.85 million for the last year, both up from previous figures. Basic earnings per share increased to SAR 3.99 from SAR 3.29, highlighting solid profitability improvements.

SASE:4016 Earnings and Revenue Growth as at Apr 2025
SASE:4016 Earnings and Revenue Growth as at Apr 2025

Future Care Trading (SASE:9544)

Simply Wall St Value Rating: ★★★★★★

Overview: Future Care Trading Co. operates in the Kingdom of Saudi Arabia, offering home medical and laboratory services, with a market cap of SAR3.33 billion.

Operations: The primary revenue stream for Future Care Trading Co. is derived from healthcare facilities and services, generating SAR52.91 million. The company's financial performance can be further analyzed by examining its gross profit margin, which reflects the efficiency of its core operations in managing costs relative to sales.

Future Care Trading, a nimble player in the Middle East healthcare sector, has shown impressive earnings growth of 106.9% over the past year, outpacing the industry average of 16.5%. Despite this recent surge, its earnings have declined by 40.4% annually over the last five years. The company operates debt-free and boasts high-quality earnings, reflecting strong operational efficiency. Over time, Future Care's free cash flow has fluctuated significantly from US$13 million in late 2020 to US$11 million by mid-2025. These figures suggest a dynamic yet volatile financial landscape for potential investors to consider carefully.

SASE:9544 Debt to Equity as at Apr 2025
SASE:9544 Debt to Equity as at Apr 2025

Hilan (TASE:HLAN)

Simply Wall St Value Rating: ★★★★★★

Overview: Hilan Ltd. is a software as a service (SaaS) provider that develops solutions for managing enterprise human capital in Israel, with a market capitalization of ₪5.44 billion.

Operations: Hilan generates revenue primarily from Business Information Services, contributing ₪1.64 billion, followed by Payroll Services, Human Resources and Organizational Systems at ₪524.77 million. The Marketing of Software Products segment adds another ₪363.90 million, while Computer Infrastructure accounts for ₪321.50 million in revenue.

Hilan, a nimble player in the professional services sector, exhibits robust financial health with cash reserves surpassing its total debt. The company has demonstrated impressive earnings growth of 14% over the past year, outpacing the industry average of 11.3%. Its debt to equity ratio has significantly improved from 30% to 5.3% over five years, reflecting prudent financial management. Recent earnings reveal a net income increase to ILS 246.52 million from ILS 216.16 million last year, alongside basic earnings per share rising to ILS 10.75 from ILS 9.42, suggesting solid operational performance and potential for continued growth in value.

TASE:HLAN Earnings and Revenue Growth as at Apr 2025
TASE:HLAN Earnings and Revenue Growth as at Apr 2025

Key Takeaways

Want To Explore Some Alternatives?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.